Journals / Kocaeli Tıp Dergisi / 2020 / Cilt: 9 - Sayı: 1

Ursodeoksikolik Asidin Streptozosin ile Diyabet Oluşturulmuş Farelerde Kardiyomyopatideki Antiinflamatuar ve Anti-Fibrotik Etkileri

Anti-Inflammatory and Anti-Fibrotic Effects of Ursodeoxycholic Acid in Streptozocin-Induced Diabetic Rats

Pages
83–88
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Diabetik hastalarda ursodeoksikolik asidin ilaç olarak kullanımı klinik olarak fayda gösterebilir.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:GİRİŞ ve AMAÇ: Diabetik kardiyomyopati, serbest yağ aside oksidasyonu, mitokondrial disfonksiyon, oksidatif stress ve diffuz miyokardiyal fibrozise seconder olarak gelişmektedir.
📊
Key Findings & Data:Bu deneysel çalışmada, ursodeoksikolik asidin streptozocin ile tetiklenmiş diabetik fare modelinde anti-inflamatuar ve antifibrotik etkilerini araştırmayı hedefledik.
💡
Conclusion & Impact:Diabetik hastalarda ursodeoksikolik asidin ilaç olarak kullanımı klinik olarak fayda gösterebilir.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

GİRİŞ ve AMAÇ: Diabetik kardiyomyopati, serbest yağ aside oksidasyonu, mitokondrial disfonksiyon, oksidatif stress ve diffuz miyokardiyal fibrozise seconder olarak gelişmektedir. Bu deneysel çalışmada, ursodeoksikolik asidin streptozocin ile tetiklenmiş diabetik fare modelinde anti-inflamatuar ve antifibrotik etkilerini araştırmayı hedefledik. YÖNTEM ve GEREÇLER: Sprague Dawley albino 30 erişkin fare 3 gruba ayrıldı: Grup-1: kontrol grubu (n=10); Grup-2 (n=10) diabetik fare grubu; Grup-3 (n=10) ursodeoksikolik asit verilen diabetic fare grubu. Histopatolojik ve biyokimyasal değerlendirmeler 4 hafta sonra kalp dokusundan yapıldı. Fibronektin ve TGF-β immunekspresyonu, TGF-β, malondialdehid, pentraxin-3, pro-BNP ve troponin-T düzeyleri ölçüldü. BULGULAR: Fibronektin immunekspresyonu, TGF-β, pentraxin-3, troponin-t, pro-BNP ve malondialdehid düzeyleri diabetik farelerde control grubuna göre anlamlı olarak artmış saptandı. Ursodeoksikolik asidin inflamasyon belirteçlerini ve fibroz düzeyini anlamlı olarak azalttığı izlendi TARTIŞMA ve SONUÇ: Bu deneysel çalışmada, ursodeoksikolik asidin diabetik farelerde anti-inflammatuar ve anti-fibrotik etkilerini gösterdik. Diabetik hastalarda ursodeoksikolik asidin ilaç olarak kullanımı klinik olarak fayda gösterebilir.

Özet

INTRODUCTION: Diabetic cardiomyopathy is a consequence of free fatty acid oxidation, dysfunction in mitochondria, oxidative stress and diffuse myocardial fibrosis. We aimed to investigate the anti-inflammatory and anti-fibrotic effect of ursodeoxycholic acid in streptozocin-induced diabetic rat model. METHODS: Male Sprague Dawley albino mature rats were divided into 3 groups: Group 1 (n=10) control group; group 2 (n=10) diabetic rats group; group 3 (n=10): diabetic rats treated with ursodeoxycholic acid group. Diabetes mellitus model was established after injection of intraperitoneal streptozocin. Histopathological and biochemical examinations were done after 4 weeks from heart tissues. Immunoexpression levels of fibronectin and TGF-β were obtained. Malondialdehyde levels were used to determine lipid peroxidation and pentraxin-3 levels were used to determine inflammation. Myocardial damage was also determined with troponin-T and pro-BNP levels. RESULTS: Cardiac muscle cell thickness (hypertrophy), TGFβ levels, fibronectin immunoexpression malondialdehyde, pentraxin-3, troponin-T and pro-BNP levels were increased significantly in groups 2 and 3 when compared to control group. Administration of ursodeoxycholic acid significantly reduced inflammation and fibrosis in group 3 compared to group 2. DISCUSSION AND CONCLUSION: In this experimental study, we demonstrated the anti-inflammatory and anti-fibrotic effects of UDCA on diabetic rats and it can be a good drug candidate for DM patients

🔖

Cite This Article

CANBOLAT, İ. P., YİĞİTTÜRT, G., ERBAŞ, O. (2020). Ursodeoksikolik Asidin Streptozosin ile Diyabet Oluşturulmuş Farelerde Kardiyomyopatideki Antiinflamatuar ve Anti-Fibrotik Etkileri. Kocaeli Tıp Dergisi, Cilt: 9 - Sayı: 1, 83–88. https://ajindex.com/articles/164690

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. International Diabetes Federation. Global Burden: Prevalence and Projections, 2015 and 2040. International Diabetes Federation; 2017.
  2. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1879–84
  3. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008; 121: 748-57. 4. van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Lipotoxicity in type 2 diabetic cardiomyopathy. Cardio¬vasc Res 2011; 92: 10-8
  4. Aragno M, Mastrocola R, Medana C, Catalano MG, Vercellinatto I, Danni O, et al. Oxidative stressdependent impairment of cardiac-specific tran¬scription factors in experimental diabetes. Endocrinology 2006; 147: 5967-74
  5. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014; 57: 660–71
  6. Makino I, Tanaka H. From a choleretic to an immunomodulator: historical review of ursodeoxycholic acid as a medicament. Journal of gastroenterology and hepatology 1998; 13: 659–64
  7. Rodrigues CM, Fan G, Wong PY, Kren BT and Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acidinduced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998; 4: 165- 78
  8. Lukivskaya O, Patsenker E and Buko VU. Protective effect of ursodeoxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: link with oxidative stress. Life Sci 2007; 80: 2397-402
  9. Mahmoud AAA, Elshazly SM. Ursodeoxycholic Acid Ameliorates Fructose-Induced Metabolic Syndrome in Rats. PLoS ONE 2014; 9: e106993
  10. Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopa¬thy: pathophysiology and clinical features. Heart Fail Rev 2013; 18: 149-66
  11. Lee W, Kim J. Diabetic cardiomyopathy: where we are and where we are going. Korean J Intern Med 2017; 32: 404-21
  12. Tschope C, Walther T, Escher F, Spillmann F, Du J, Altman C, et al. Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J. 2005; 19: 2057–9
  13. Westermann D, van Linthout S, Dhayat S, Dhayat N, Escher F, Bücker-Gartner C, et al. Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental di